Indication · GI, Urology & Nephrology
Prostate cancer
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
112
Cleared or approved since 2000
PMA and De Novo
71
Higher-risk or first-of-kind devices
Breakthrough devices
4
Authorized through June 30, 2026
Recruiting device trials
87
532 device trials in all
Breakthrough-designated devices
- IsoPSA AssayCleveland Diagnostics, Inc. · 2025
- ArteraAI ProstateArtera, Inc. · 2025
- Galen Second ReadIbex Medical Analytics , Ltd. · 2025
1 more devices with a free account
Devices
112 devices. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- Elecsys total PSA, total PSA CalSet II
Roche Diagnostics Corp. · PMA · Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer · newest 2023 · 11 decisions
- Elecsys free PSA, free PSA CalSet
Roche Diagnostics Corp. · PMA · Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions · newest 2023 · 8 decisions
- ARCHITECT Total PSA, Alinity i Total PSA
Abbott Laboratories · PMA · Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer · newest 2023 · 7 decisions
57 more devices with a free account
Showing the first 60. Narrow by pathway, or open a device type below.
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
- The Vanguard Study: Testing a New Way to Screen for CancerPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06995898 · 24,000 participants (planned) · Start Jun 18, 2025 · Primary completion Jan 31, 2029
Device: Device Usage · For: Bladder Carcinoma; Breast Carcinoma; Colorectal Carcinoma and 8 more
Sites: Pleasanton, California; San Diego, California; Cheyenne Wells, Colorado · 49 sites in all
- Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate CancerNot yet recruiting
University of ZurichAcademic, hospital or other
NCT07591051 · 54 participants (planned) · Start Jan 2027 · Primary completion Jul 2029
Device: weekly CT or MR online adaptive definitive SBRT · For: Prostate Cancer
Sites: Heidelberg, Germany; Zurich, Switzerland
- Effectiveness of the SpaceOAR Vue System in Subjects With Prostate CancerPivotal-lookingActive, not recruiting
Boston Scientific CorporationPublic (BSX)
NCT04905069 · 500 participants · Start Dec 21, 2021 · Primary completion Dec 2027
Device: SpaceOAR Vue System · For: Prostate Cancer
Sites: Fort Myers, Florida; Tampa, Florida; Kansas City, Kansas · 30 sites in all
529 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
- Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers (LTJ)31
- Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer (MTF)20
- Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions (MTG)16
- Antigen(Complexed),Prostate Specific,(Cpsa) (NAF)10
- High Intensity Ultrasound System For Prostate Tissue Ablation (PLP)8
- Hydrogel Spacer (OVB)7
- Prostate Immobilizer Rectal Balloon (PCT)5
- Probe And Director, Gastro-Urology (FGM)4
- Software Algorithm Device To Assist Users In Digital Pathology (QPN)2
- Multi-Analyte Test System With Algorithmic Analysis For Detection Of Prostate Cancer (QRF)2
- Seed, Isotope, Gold, Titanium, Platinum (IWG)1
- Acid Phosphatase (Prostatic), Tartrate Inhibited (JFH)1
- Immunohistochemical Reagent, Antibody (Monoclonal Or Polyclonal) To P63 Protein In Nucleus Of Prostatic Basal Cells (NTR)1
- Prostate Lesion, Documentation, System (OQT)1
- Prostate-Specific Antigen (Psa) For Prognostic, Recurrence Risk Assessment Of Prostate Cancers (OWM)1
- P2psa (OYA)1
- Pathology Software Algorithm Device Analyzing Digital Images For Prostate Cancer Prognosis (SFH)1
Research
- Device studies on prostate cancer across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.